TransMedics Group (TMDX) Competitors

AxoGen (NASDAQ:AXGN) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Which has stronger earnings & valuation, AXGN or TMDX?

AxoGen has higher earnings, but lower revenue than TransMedics Group. AxoGen is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$159.01M	3.50	-$21.72M	-$0.32	-39.50
TransMedics Group	$401.09M	6.73	-$25.03M	$0.94	85.62

Do analysts recommend AXGN or TMDX?

AxoGen currently has a consensus price target of $15.00, suggesting a potential upside of 18.67%. TransMedics Group has a consensus price target of $144.80, suggesting a potential upside of 79.92%. Given TransMedics Group's higher probable upside, analysts clearly believe TransMedics Group is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
TransMedics Group	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do institutionals & insiders believe in AXGN or TMDX?

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 7.0% of AxoGen shares are owned by company insiders. Comparatively, 7.0% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is AXGN or TMDX more profitable?

TransMedics Group has a net margin of 8.14% compared to AxoGen's net margin of -7.91%. TransMedics Group's return on equity of 18.74% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-7.91%	-14.91%	-7.49%
TransMedics Group	8.14%	18.74%	4.39%

Which has more risk & volatility, AXGN or TMDX?

AxoGen has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.

Does the media prefer AXGN or TMDX?

In the previous week, TransMedics Group had 13 more articles in the media than AxoGen. MarketBeat recorded 16 mentions for TransMedics Group and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.25 beat TransMedics Group's score of 0.93 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	10 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor AXGN or TMDX?

AxoGen received 348 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 72.71% of users gave AxoGen an outperform vote while only 59.32% of users gave TransMedics Group an outperform vote.

Company	Underperform	Outperform
AxoGen	Outperform Votes 453 72.71%	Underperform Votes 170 27.29%
TransMedics Group	Outperform Votes 105 59.32%	Underperform Votes 72 40.68%

Summary

TransMedics Group beats AxoGen on 14 of the 18 factors compared between the two stocks.